Immunovant, Inc.
- Open
- 40.99
- Day high
- 41.27
- Day low
- 39.92
- Prev close
- 41.20
- Volume
- 1.3M
- Mkt cap
- $8.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 11.5
- P/S
- 1188.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$4.5M over the last 3 months (0 open-market buys, 24 sales)
- 🏛Institutions accumulating (13F)
Immunovant, Inc. (IMVT) is a Healthcare company listed on NASDAQ. The stock is up 166% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 24 sales (SEC Form 4).
Immunovant, Inc. (IMVT) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IMVT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.63 | $-0.75 | -19.3% | $7M | +0.0% |
| May 20, 2026 | $-0.60 | $-0.73 | -21.7% | — | — |
| Feb 6, 2026 | $-0.72 | $-0.61 | +15.3% | — | — |
| May 29, 2025 | $-0.71 | $-0.64 | +10.3% | — | — |
| Feb 6, 2025 | $-0.73 | $-0.76 | -4.1% | — | — |
| Nov 7, 2024 | $-0.60 | $-0.74 | -23.3% | — | — |
| May 29, 2024 | $-0.43 | $-0.52 | -20.9% | — | — |
| Nov 9, 2023 | $-0.47 | $-0.45 | +4.3% | — | — |
| Aug 10, 2023 | $-0.45 | $-0.57 | -26.7% | — | — |
| May 22, 2023 | $-0.43 | $-0.46 | -7.0% | — | — |
| Feb 3, 2023 | $-0.39 | $-0.49 | -25.6% | — | — |
| Nov 4, 2022 | $-0.39 | $-0.41 | -5.1% | — | — |
IMVT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Pande Atuldirector | Sell | 1,500 | $43.27 |
| Aug 28, 2026 | Pande Atuldirector | Option | 1,500 | $8.43 |
| Aug 21, 2026 | Gloria Melanieofficer: Chief Operating Officer | Sell | 3,056 | $44.16 |
| Jul 24, 2026 | Pande Atuldirector | Option | 1,500 | $8.43 |
| Jul 24, 2026 | Pande Atuldirector | Sell | 1,500 | $39.80 |
| Jul 24, 2026 | Stout Jay Sofficer: Chief Technology Officer | Sell | 2,857 | $38.69 |
| Jul 24, 2026 | Girao Tiagoofficer: Chief Financial Officer | Sell | 6,798 | $38.69 |
| Jul 10, 2026 | Gloria Melanieofficer: Chief Operating Officer | Sell | 106 | $39.99 |
| Jul 10, 2026 | Van Tuyl Christopherofficer: Chief Legal Officer | Sell | 63 | $39.99 |
| Jul 10, 2026 | Van Tuyl Christopherofficer: Chief Legal Officer | Sell | 1,143 | $39.53 |
| Jul 10, 2026 | Stout Jay Sofficer: Chief Technology Officer | Sell | 1,906 | $39.53 |
| Jul 10, 2026 | Stout Jay Sofficer: Chief Technology Officer | Sell | 1,399 | $39.53 |
| Jul 10, 2026 | Gloria Melanieofficer: Chief Operating Officer | Sell | 1,930 | $39.53 |
| Jul 10, 2026 | Stout Jay Sofficer: Chief Technology Officer | Sell | 105 | $39.99 |
| Jul 10, 2026 | Stout Jay Sofficer: Chief Technology Officer | Sell | 77 | $39.99 |
Source: IMVT SEC Form 4 filings, latest Aug 28, 2026. For informational purposes only — not investment advice.
See the full IMVT insider & 13F page →Immunovant, Inc. company profile
Overview
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Business
Immunovant operates in the biotechnology sector, specifically focusing on developing treatments for autoimmune diseases. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy cells and tissues, leading to conditions such as myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia. The company's core product is batoclimab, a novel fully human monoclonal antibody that represents a breakthrough approach to treating autoimmune conditions. Batoclimab works by selectively binding to and inhibiting the neonatal fragment crystallizable receptor (FcRn). The FcRn receptor plays a crucial role in recycling antibodies in the body - it essentially acts as a recycling system that prevents antibodies from being broken down, allowing them to circulate longer in the bloodstream. In autoimmune diseases, harmful antibodies attack the body's own tissues, so by blocking this recycling mechanism, batoclimab reduces the levels of these disease-causing antibodies. Currently, batoclimab is being tested in Phase IIa clinical trials for myasthenia gravis (a neuromuscular disorder causing muscle weakness) and thyroid eye disease (an inflammatory condition affecting the eyes). The company has also initiated Phase II trials for warm autoimmune hemolytic anemia, a blood disorder where antibodies destroy red blood cells. As a clinical-stage company, Immunovant has not yet generated meaningful product revenue, with the company focusing entirely on research and development activities.
Revenue model
As a clinical-stage biopharmaceutical company, Immunovant does not currently generate revenue from product sales. The company operates on a research and development model typical of early-stage biotech firms, funding its operations through equity financing and partnerships while advancing its drug candidates through clinical trials. The company's future revenue model will likely depend on successfully bringing batoclimab to market, at which point it would generate income through direct product sales to healthcare providers and patients, or through licensing agreements with larger pharmaceutical companies. The autoimmune disease market represents a significant commercial opportunity, as these conditions often require long-term treatment and affect millions of patients worldwide. Several factors could impact Immunovant's future profitability and margins. Positive clinical trial results would increase the likelihood of regulatory approval and market success, while negative results could significantly impact the company's prospects. The competitive landscape in autoimmune treatments is intensifying, with both established pharmaceutical companies and other biotech firms developing alternative approaches. Manufacturing costs, pricing pressures from healthcare systems, and the need for extensive clinical evidence to demonstrate superiority over existing treatments will all influence future margins. Additionally, the company's relationship with parent company Roivant Sciences provides both strategic support and potential constraints on independent decision-making.
Competitive moat
Immunovant's competitive moat is currently limited but has potential to strengthen significantly if batoclimab proves successful. The company's primary advantage lies in its novel mechanism of action targeting the FcRn receptor, which represents a relatively new approach to treating autoimmune diseases. This mechanism could potentially offer advantages over existing treatments by providing more targeted therapy with fewer side effects. However, the company's moat remains fragile at this clinical stage. The biotechnology industry is characterized by high failure rates, with many promising drug candidates failing in late-stage clinical trials. Immunovant faces competition from both established pharmaceutical companies with approved autoimmune treatments and other biotech firms pursuing similar or alternative approaches. Large pharmaceutical companies possess significantly greater resources for research, development, and marketing, and could potentially develop competing FcRn-targeting therapies. The company's association with Roivant Sciences provides some strategic advantages through shared expertise and resources, but this relationship also means Immunovant operates within a larger corporate structure that may limit its flexibility. If batoclimab successfully completes clinical trials and gains regulatory approval, the company could establish a stronger competitive position through patent protection, clinical data exclusivity, and first-mover advantages in specific indications. Until then, the moat remains primarily dependent on execution risk and clinical success.
Risks & safety
Immunovant maintains a relatively strong financial position for a clinical-stage biotech company, though it faces typical cash burn challenges. • Cash Position: Strong liquidity with $714 million in cash and short-term investments as of Q4 2025, providing substantial runway for operations • Debt Level: Minimal debt with debt-to-equity ratio of only 0.0001, indicating very low financial leverage risk • Cash Burn: High operating cash outflow of $376 million annually (FY 2025), suggesting approximately 1.9 years of runway at current burn rate • Current Ratio: Excellent short-term liquidity with current ratio of 11.16, indicating strong ability to meet near-term obligations • Valuation Metrics: Trading at negative P/E ratios due to losses, but Graham net-net ratio of 4.27 suggests potential asset value relative to market cap • Solvency Risk: Low near-term bankruptcy risk given strong cash position, but long-term viability depends on clinical success or additional financing • Other Considerations: As a subsidiary of Roivant Sciences, potential access to additional capital, but also subject to parent company strategic decisions
Recent development
Based on the financial data trends, Immunovant has been steadily advancing its clinical programs while managing increased research and development expenses. The company's cash burn has increased significantly from approximately $214 million in FY 2024 to $376 million in FY 2025, reflecting the intensification of clinical trial activities across multiple indications. The progression of batoclimab through Phase II trials represents the company's primary strategic focus, with trials now active in three different autoimmune conditions: myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia. This multi-indication approach suggests a strategy to maximize the commercial potential of the FcRn-targeting mechanism while diversifying clinical risk across different patient populations. The company's minimal revenue generation ($160,000 in Q4 2025 compared to zero in previous quarters) likely represents milestone payments or collaboration income rather than product sales, as batoclimab has not yet reached commercialization. The substantial increase in operating expenses and cash burn indicates the company is in an intensive phase of clinical development, which is typical for biotech companies advancing multiple late-stage trials simultaneously.
IMVT company profile · for informational purposes only — not investment advice.
Track IMVT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free